Skip to main content

Table 1 The frequencies of relapsed and secondary acute myeloid leukemia (AML), signs of differentiation (FAB subclasses, CD34 expression) and genetic abnormalities among unselected AML patients unfit for intensive therapy

From: The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

FAB classification  
  M0/M1 0.41
  M2 0.23
  M4/M5 0.36
Expression of CD34 (> 20% positive cells) 0.70
Cytogenetic abnormalities  
  Normal 0.50
  Good 0.00
  Intermediate 0.20
  Adverse 0.30
Flt3- internal tandem duplication 0.40
NPM-1 mutation 0.35